Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products. Consider Pfizer. The company’s inability to accurately project demand for its Covid-19 ...
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...
Investor's Business Daily on MSN15h
Merck Stock Plummets 9% As Gardasil Dynamics, 2025 Guidance Weigh On SharesInvestors hammered Merck stock Tuesday after the company beat fourth-quarter expectations, but delivered a light 2025 outlook.
Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...
Merck, the giant pharmaceutical company with multiple facilities in eastern Pennsylvania and New Jersey, isn’t too enthused about its prospects in 2025.
The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begin in 2028.
Truist Securities expressed confidence in its latest note that Merck will be able to navigate the upcoming Gardasil headwinds ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback